EP 2603527 A1 20130619 - HUMANIZED EGFR ANTIBODIES
Title (en)
HUMANIZED EGFR ANTIBODIES
Title (de)
HUMANISIERTE EGFR-ANTIKÖRPER
Title (fr)
ANTICORPS ANTI-EGFR HUMANISÉS
Publication
Application
Priority
- US 37218610 P 20100810
- EP 10008319 A 20100810
- EP 2010004880 W 20100810
- EP 2011063781 W 20110810
- EP 11748614 A 20110810
Abstract (en)
[origin: WO2012020059A1] The present invention pertains to humanized anti-EGFR antibodies having antigen binding properties similar to those of the murine or chimeric anti-EGFR antibody from which they are derived. In particular, the present invention is directed to humanized anti-EGFR antibodies which are useful in the treatment of cancer.
IPC 8 full level
A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC (source: EP)
A61P 35/00 (2017.12); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/94 (2013.01)
Citation (search report)
See references of WO 2012020059A1
Citation (examination)
MAGDELAINE-BEUZELIN ET AL: "Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 64, no. 3, 14 November 2007 (2007-11-14), pages 210 - 225, XP022344458, ISSN: 1040-8428, DOI: 10.1016/J.CRITREVONC.2007.04.011
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2012020059 A1 20120216; BR 112013003257 A2 20160614; CN 103025760 A 20130403; EP 2603527 A1 20130619
DOCDB simple family (application)
EP 2011063781 W 20110810; BR 112013003257 A 20110810; CN 201180036437 A 20110810; EP 11748614 A 20110810